Thus far, SHP-2 has been identified as an oncogene in gastric cancer and breast cancer (Table 3), which warrants further investigation into the RTK-SHP-2 axis and inhibition of SHP-2 as a potential future therapeutic. This evidence concerns the gene PTPN11 and breast carcinoma.